- Home
- PRK vs RDY Comparison
PRK vs RDY Comparison
Compare PRK & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRK
- RDY
- Stock Information
- Founded
- PRK 1908
- RDY 1984
- Country
- PRK United States
- RDY India
- Employees
- PRK N/A
- RDY N/A
- Industry
- PRK Major Banks
- RDY Biotechnology: Pharmaceutical Preparations
- Sector
- PRK Finance
- RDY Health Care
- Exchange
- PRK Nasdaq
- RDY Nasdaq
- Market Cap
- PRK 2.6B
- RDY 2.1B
- IPO Year
- PRK N/A
- RDY N/A
- Fundamental
- Price
- PRK $172.01
- RDY $14.90
- Analyst Decision
- PRK Hold
- RDY Strong Buy
- Analyst Count
- PRK 1
- RDY 2
- Target Price
- PRK $170.00
- RDY $16.95
- AVG Volume (30 Days)
- PRK 58.9K
- RDY 1.7M
- Earning Date
- PRK 07-21-2025
- RDY 07-28-2025
- Dividend Yield
- PRK 2.56%
- RDY 0.54%
- EPS Growth
- PRK 23.42
- RDY 1.47
- EPS
- PRK 9.75
- RDY 0.79
- Revenue
- PRK $515,788,000.00
- RDY $3,809,801,863.00
- Revenue This Year
- PRK $7.96
- RDY $10.24
- Revenue Next Year
- PRK $3.31
- RDY N/A
- P/E Ratio
- PRK $17.16
- RDY $18.76
- Revenue Growth
- PRK 10.66
- RDY 16.61
- 52 Week Low
- PRK $137.97
- RDY $12.26
- 52 Week High
- PRK $207.99
- RDY $16.89
- Technical
- Relative Strength Index (RSI)
- PRK 66.03
- RDY 45.51
- Support Level
- PRK $163.07
- RDY $15.12
- Resistance Level
- PRK $174.26
- RDY $15.71
- Average True Range (ATR)
- PRK 2.86
- RDY 0.21
- MACD
- PRK 1.11
- RDY -0.13
- Stochastic Oscillator
- PRK 87.20
- RDY 5.56
About PRK Park National Corporation
Park National Corp is a diversified financial services company based in Newark, Ohio, consisting of 11 community banking divisions with more than 100 offices in Ohio and Kentucky. Park National provides banking and other financial services to consumers and businesses.
About RDY Dr. Reddy's Laboratories Ltd
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.